Abstract
Hyperthermic intrathoracic chemotherapy (HITHOC) has been used in addition to radical surgery for primary and secondary pleural malignancies to improve local control, prolong survival, and improve the quality of life. This study was performed to study the indications, methodology, perioperative outcomes, and survival in patients undergoing HITHOC at Indian centers. A retrospective analysis of prospectively collected demographic and clinical data, perioperative and survival data of patients undergoing surgery with or without HITHOC was performed. From January 2011 to May 2018, seven patients underwent pleurectomy/decortication (P/D) or extrapleural pneumonectomy (EPP) with HITHOC and four had P/D or EPP alone at three Indian centers. P/D was performed in two and EPP in nine patients. The primary tumor was pleural mesothelioma in eight, metastases from thymoma in one, germ cell tumor in one, and solitary fibrous tumor of the pleura in one. HITHOC was performed using cisplatin. Grade 3–4 complications were seen in one patient in the HITHOC group and none in the non-HITHOC group, and one patient in the non-HITHOC group died of complications. At a median follow-up of 9 months, five patients of the HITHOC group were alive, four without recurrence, and one with recurrence. One patient in the non-HITHOC group was alive and disease-free at 24 months, and two died of progression at 18 and 36 months. HITHOC can be performed without increasing the morbidity of P/D or EPP. Most of these patients require multimodality treatment and are best managed by multidisciplinary teams.
Similar content being viewed by others
References
Ried M, Potzger T, Braune N, Neu R, Zausig Y, Schalke B et al (2013) Cytoreductive surgery and hyperthermic intrathoracic chemotherapy perfusion for malignant pleural tumours: perioperative management and clinical experience. Eur J Cardiothorac Surg 43(4):801–807. https://doi.org/10.1093/ejcts/ezs418
Shapiro M, Korst RJ (2014) Surgical approaches for stage iva thymic epithelial tumors. Front Oncol 3:332. Published 2014 Jan 14. https://doi.org/10.3389/fonc.2013.00332
Migliore M (2017) Debulking surgery and hyperthermic intrathoracic chemotherapy (HITHOC) for lung cancer. Chin J Cancer Res 29(6):533–534
Cao C, Tian D, Park J, Allan J, Pataky KA, Yan TD (2014) A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma. Lung Cancer 83:240–245
DaSilva MC et al (2010) Technique of extrapleural pneumonectomy. Oper Tech Thorac Cardiovasc Surg 15(4):282–293
Rusch VW, Niedzwiecki D, Tao Y, Menendez-Botet C, Dnistrian A, Kelsen D, Saltz L, Markman M (1992) Intrapleural cisplatin and mitomycin for malignant mesothelioma following pleurectomy: pharmacokinetic studies. J Clin Oncol 10:1001–1006
Lerza R, Esposito M, Vannozzi M, Bottino GB, Bogliolo G, Pannacciulli I (1994) High doses of intrapleural cisplatin in a case of malignant pleural mesothelioma. Cancer 73:79–84
United States Department of Public Health and Hu- man Services, NIH, NCI: Common toxicity criteria for adverse events (CTCAE) (2010) National Cancer Institute. http://evs.nci.nih.gov/ftp1/CTCAE_Vers._4.03_2010–06-14;_QuickReference_5x7.pdf. Accessed 31 Oct 2018
Tilleman TR, Richards WG, Zellos L, Johnson BE, Jaklitsch MT, Mueller J, Yeap BY, Mujoomdar AA, Ducko CT, Bueno R, Sugarbaker DJ (2009) Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study. J Thorac Cardiovasc Surg 138:405–411
Isik AF, Sanli M, Yilmaz M, Meteroglu F, Dikensoy O, Sevinc A, Camci C, Tuncozgur B, Elbeyli L (2013) Intrapleural hyperthermic perfusion chemotherapy in subjects with metastatic pleural malignancies. Respir Med 107:762–767
van Sandick JW, Kappers I, Baas P, Haas RL, Klomp HM (2008) Surgical treatment in the management of malignant pleural mesothelioma: a single institution’s experience. Ann Surg Oncol 15:1757–1764
Sugarbaker PH, Stuart OA, Eger C (2012) Pharmacokinetics of hyperthermic intrathoracic chemotherapy following pleurectomy and decortication. Gastroenterol Res Pract 2012:471205
Collaud S, de Perrot M (2012) Technical pitfalls and solutions in extrapleural pneumonectomy. Ann Cardiothorac Surg 1(4):537–543
Zhao ZY, Zhao SS, Ren M, Liu ZL, Li Z, Yang L (2017) Effect of hyperthermic intrathoracic chemotherapy on the malignant pleural mesothelioma: a systematic review and meta-analysis. Oncotarget 8(59):100640–100647. Published 2017 Oct 19. https://doi.org/10.18632/oncotarget.22062
Ried M, Hofmann HS, Dienemann H, Eichhorn M (2018) Implementation of hyperthermic intrathoracic chemotherapy (hithoc) in Germany. Zentralbl Chir 143(3):301–306. https://doi.org/10.1055/a-0573-2419
Liu L, Zhang N, Min J, Su H, Wang H, Chen D, Sun L, Zhang H, Li W, Zhang H (2016) Retrospective analysis on the safety of 5,759 times of bedside hyperthermic intra-peritoneal or intra-pleural chemotherapy (HIPEC). Oncotarget 7:21570–21578. https://doi.org/10.18632/oncotarget.7622
Cao C, Tian D, Park J, Allan J, Pataky KA, Yan TD (2014) A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma. Lung Cancer 83(2):240–245. https://doi.org/10.1016/j.lungcan.2013.11.026
Rao S (2009) Malignant pleural mesothelioma. Lung India 26(2):53–54
Sugarbaker DJ, Gill RR, Yeap BY, Wolf AS, DaSilva MC, Baldini EH, Bueno R, Richards WG (2013) Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection. J Thorac Cardiovasc Surg 145:955–963
Ried M, Potzger T, Sziklavari Z, Diez C, Neu R, Schalke B et al (2013) Extended surgical resections of advanced thymoma Masaoka stages III and IVa facilitate outcome. Thorac Cardiovasc Surg. https://doi.org/10.1055/s-0033-1345303
Weder W, Stahel RA, Bernhard J, Bodis S, Vogt P, Ballabeni P, Lardinois D, Betticher D, Schmid R, Stupp R, Ris H, Jermann M, Mingrone W, Roth A, Spiliopoulos A, On behalf of the Swiss Group for Clinical Cancer Research (2007) Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol 18:1196–1202
Krug LM, Pass HI, Rusch VW, Kindler HL, Sugarbaker DJ, Rosenzweig KE, Flores R, Friedberg JS, Pisters K, Monberg M, Obasaju CK, Vogelzang NJ (2009) Multicenter phase II trial of neoadjuvant pemetrexed lus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 27:3007–3013
Nakas A, Black E, Entwisle J, Muller S, Waller DA (2010) Surgical assessment of malignant pleural mesothelioma: have we reached a critical stage? Eur J Cardiothorac Surg 37:1457–1463
Belcher E, Hardwick T, Lal R, Marshall S, Spicer J, Lang-Lazdunski L (2011) Induction chemotherapy, cytoreductive surgery and intraoperative hyperthermic pleural irrigation in patients with stage IVA thymoma. Interact Cardiovasc Thorac Surg 12(5):744–747. https://doi.org/10.1510/icvts.2010.255307
Yellin A, Simansky DA, Ben-Avi R, Perelman M, Zeitlin N, Refaely Y et al (2013) Resection and heated pleural chemoperfusion in patients with thymic epithelial malignant disease and pleural spread: a single-institution experience. J Thorac Cardiovasc Surg 145(1):83–87 discussion 87–9. https://doi.org/10.1016/j.jtcvs.2012.10.013
Zhou H, Wu W, Tang X, Zhou J, Shen Y (2017) Effect of hyperthermic intrathoracic chemotherapy (HITHOC) on the malignant pleural effusion: a systematic review and meta-analysis. Medicine (Baltimore) 96(1):e5532
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no conflicts of interest.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Patel, M.D., Damodaran, D., Rangole, A. et al. Hyperthermic Intrathoracic Chemotherapy (HITHOC) for Pleural Malignancies—Experience from Indian Centers. Indian J Surg Oncol 10 (Suppl 1), 91–98 (2019). https://doi.org/10.1007/s13193-018-0859-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13193-018-0859-y